Successful and Safe Treatment With 177Lu-DOTATATE (Lutathera) of Progressive Metastatic Pancreatic Neuroendocrine Tumor Under Hemodialysis
| Autor: | Brillouet Séverine, Guimbaud Rosine, Bensafi Amel, Mokrane Fatima, Lawrence Dierickx |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Pancreatic neuroendocrine tumor medicine.medical_treatment Neuroendocrine tumors Octreotide Gastroenterology 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Coordination Complexes Renal Dialysis Internal medicine medicine 177Lu-DOTATATE Humans Radiology Nuclear Medicine and imaging Embolization Aged Chemotherapy business.industry General Medicine medicine.disease Embolization Therapeutic Pancreatic Neoplasms Neuroendocrine Tumors Somatostatin Treatment Outcome 030220 oncology & carcinogenesis Radionuclide therapy Disease Progression Female Hemodialysis Safety business |
| Zdroj: | Clinical nuclear medicine. 45(9) |
| ISSN: | 1536-0229 |
| Popis: | Lu-DOTATATE is an effective treatment for inoperable metastatic well-differentiated pancreatic neuroendocrine tumors. There are no guidelines for patients with terminal renal failure. We present the case of a 74-year-old woman who received different lines of treatment: analogs of somatostatin, chemotherapy, a first series of peptide receptor radionuclide therapy (PRRT), and finally chemoembolization. Because of persistent hepatic progression, a safe and successful administration of 4 cycles of a second series of PRRT under hemodialysis was administered. Patient was in scintigraphic complete remission at 12 months with normal hematological parameters at 12 and 30 months after PRRT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|